$MOBI

Leavitt Chase C. purchased $21K of MOBI

Leavitt Chase C. (SEE REMARKS) purchased 2,000 shares of Mobia Medical, Inc. (MOBI) at $10.30 on 2026-09-11.

Original reporting
SEC EDGAR · Leavitt Chase C.
Published Sep 15, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MOBI
Neutral
medium confidence
Mentioned
$MOBI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBINeutralLow
01

Why it matters

The purchase adds 2,000 shares to the officer's holdings, a modest increase that may be viewed positively by some investors but is unlikely to affect price.

02

Market read

New insider purchase provides fresh data for traders monitoring Mobia Medical, but the small size limits actionable impact.

03

What to watch

Potential upcoming clinical milestones or financing events not disclosed in the filing.

Relevance 4/10Novelty 6/10Timing: filed Sep 15 2026

Background

Form 4 filings disclose insider trades; they are primary sources for new insider activity.

Company-level read

Ticker impact

$MOBINeutralMedium confidence
Context

Officer Leavitt Chase C. purchased 2,000 shares of Mobia Medical for $20,600, increasing holdings to 5,000 shares.

Expected impact

Minimal price movement expected; may slightly support short-term bullish sentiment.

Evidence & confidence

The transaction is under $1M and represents a modest stake increase for an officer, unlikely to move the stock materially.

Market effects

No significant sector impact; insider activity is company‑specific.

Limited to U.S. investors tracking Mobia Medical.

Negligible

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Leavitt Chase C.

    Insider who executed the purchase.

  • Mobia Medical, Inc.

    Biotech firm whose stock is affected.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

$MOBIMedAI 8/10

Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.

$MOBIMed

Mobia Medical Reports Second Quarter 2026 Financial Results

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial re

$MOBIMedAI 8/10

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.